The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution.

Abstract:

PURPOSE:To explore whether changes in tumor size impact survival in advanced non-small-cell lung cancer (NSCLC) after target therapy, especially in patients with evaluation of stable disease (SD), and to review the applicability of the Response Evaluation Criteria in Solid Tumors (RECIST) criteria in target therapy. PATIENTS AND METHODS:Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. The treatment effect (complete response, partial response, stable disease [SD], or progressive disease) was evaluated with radiologic assessment according to the RECIST criteria. SD patients were divided into two groups: SD-/0, in which the sum of the longest diameter of target lesions decreased by less than 30% or did not change; and SD+, in which the sum of the longest diameter of target lesions increased by less than 20%. The differences of progression-free survival (PFS) and overall survival (OS) between these groups were analyzed. RESULTS:In the whole group, 27 patients achieved complete response or partial response as best response, 40 achieved SD, and 22 had progressive disease. The median PFS and OS were 4 months and 11.1 months, respectively. In SD patients, 27 were SD-/0 and 13 patients were SD+. The PFS and OS of SD+ patients was shorter than that of SD-/0 patients (5.65 months vs 2.03 days, P < 0.001 and 12.2 months vs 7.1 months, P < 0.001). CONCLUSION:The applicability of RECIST criteria was called into question in the evaluation of target therapy. Change in tumor size might predict survival in advanced NSCLC patients with target therapy and may be a surrogate endpoint for efficacy in target therapy.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Zhang J,Huang Y,Li X,Guo Y,Zhao Y,Xue C,Hu Z,Zhang L,Zhao H

doi

10.2147/OTT.S38441

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

349-55

issn

1178-6930

pii

ott-5-349

journal_volume

5

pub_type

杂志文章
  • Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study.

    abstract:Purpose:Non-small cell lung cancer (NSCLC) patients with EGFR mutation are suffering from a high incidence of brain metastasis (BM). It is still controversial whether cranial radiotherapy could be delayed when the EGFR-tyrosine kinase inhibitors (TKIs) used as first-line therapy for EGFR-positive patients with BM. This...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S223216

    authors: An N,Wang H,Li J,Zhai X,Jing W,Jia W,Kong L,Zhu H,Yu J

    更新日期:2019-10-08 00:00:00

  • NOTCH1 is a poor prognostic factor for breast cancer and is associated with breast cancer stem cells.

    abstract::Recently, the human gene NOTCH1 has been found to be implicated in cancer cell metastasis and the maintenance of cancer stem cells. However, for breast cancer in particular, an association between NOTCH1 levels and metastasis has not been determined. In this study, we investigated the expression status and correlation...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S109606

    authors: Zhong Y,Shen S,Zhou Y,Mao F,Lin Y,Guan J,Xu Y,Zhang S,Liu X,Sun Q

    更新日期:2016-11-07 00:00:00

  • Upregulation of SOX18 in colorectal cancer cells promotes proliferation and correlates with colorectal cancer risk.

    abstract:Background:Since colorectal cancer (CRC) is one of the most common malignant tumors worldwide, we aimed to identify the role of sex determining region Y (SRY)-box 18 (SOX18) in CRC. Methods:RT-PCR and immunohistochemistry were employed to detect the expression of SOX18 in CRC samples. We then identified the effect of ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S178916

    authors: Miao Z,Deng X,Shuai P,Zeng J

    更新日期:2018-11-29 00:00:00

  • Inhibition of microRNA-126 promotes the expression of Spred1 to inhibit angiogenesis in hepatocellular carcinoma after transcatheter arterial chemoembolization: in vivo study.

    abstract::MicroRNA-126 (miR-126) has been found to promote angiogenesis, but the underlying mechanisms are still unclear. So, we conducted this study to explore the effect of miR-126 expression on angiogenesis in hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). The expression levels of miR-1...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S106513

    authors: Ji JS,Xu M,Song JJ,Zhao ZW,Chen MJ,Chen WQ,Tu JF,Yang XM

    更新日期:2016-07-19 00:00:00

  • FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib.

    abstract::Fibroblast growth factor receptor (FGFR) family includes four highly conserved receptor tyrosine kinases. Particularly, FGFR2 has been identified as a potential target for tyrosine kinase inhibitor (TKI) treatment. Except for immunohistochemistry and fluorescence in situ hybridization, next-generation sequencing (NGS)...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S218796

    authors: Ying X,Tu J,Wang W,Li X,Xu C,Ji J

    更新日期:2019-11-06 00:00:00

  • The role of induction and adjuvant chemotherapy in combination with concurrent chemoradiotherapy for nasopharyngeal cancer: a Bayesian network meta-analysis of published randomized controlled trials.

    abstract::Whether the addition of induction chemotherapy (IC) or adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) is superior to CCRT alone for locally advanced nasopharyngeal cancer is unknown. A Bayesian network meta-analysis was performed to investigate the efficacy of CCRT, IC + CCRT, and CCRT + AC on local...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S96983

    authors: Yu H,Gu D,He X,Gao X,Bian X

    更新日期:2016-01-05 00:00:00

  • Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma.

    abstract::The epidermal growth-factor receptor (EGFR) is overexpressed in the majority of epithelial ovarian cancers and promotes cell proliferation, migration and invasion, and angiogenesis, as well as resistance to apoptosis. This makes EGFR an attractive therapeutic target in this disease. A number of strategies to block EGF...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S30373

    authors: Hirte HW

    更新日期:2013-04-18 00:00:00

  • Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer.

    abstract::The use of additional radiotherapy for resected stage IIIA N2 non-small-cell lung cancer in the setting of standard adjuvant chemotherapy remains controversial. A comprehensive search (last search updated in March 2015) for relevant studies comparing patients with stage IIIA N2 non-small-cell lung cancer undergoing re...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S95517

    authors: Lei T,Xu XL,Chen W,Xu YP,Mao WM

    更新日期:2016-02-24 00:00:00

  • A current perspective on stereotactic body radiation therapy for pancreatic cancer.

    abstract::Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients are unable to undergo resection, which remains the only potentially curative treatment option. The management of locally advanced (unresectable) pancreatic cancer is controversial; however, treatment with either chemotherapy or c...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S99826

    authors: Hong JC,Czito BG,Willett CG,Palta M

    更新日期:2016-10-31 00:00:00

  • Predictive factors and prognosis for recurrent laryngeal nerve invasion in papillary thyroid carcinoma.

    abstract:BACKGROUND:Recurrent laryngeal nerve (RLN) invasion in papillary thyroid carcinoma (PTC) is one of the main predictors of poor prognosis. The present study investigated the risk factors for RLN invasion in PTC patients. METHODS:A total of 3,236 patients who received thyroidectomy due to PTC in Thyroid and Parathyroid ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S142799

    authors: Chen W,Lei J,You J,Lei Y,Li Z,Gong R,Tang H,Zhu J

    更新日期:2017-09-11 00:00:00

  • Diagnostic efficacy of computed tomography-guided transthoracic needle aspiration and biopsy in patients with pulmonary disease.

    abstract:BACKGROUND:Computed tomography-guided transthoracic needle aspiration (TTNA) and biopsy (TTNB) is a well established, safe, and rapid method of reaching a definitive diagnosis for most thoracic lesions. The present study aimed to determine the roles of TTNA and TTNB in the diagnosis of pulmonary diseases and to compare...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S45013

    authors: Tuna T,Ozkaya S,Dirican A,Findik S,Atici AG,Erkan L

    更新日期:2013-11-05 00:00:00

  • Deleted in breast cancer 1 as a potential prognostic biomarker in human cancers: a pooled analysis of 2,254 patients.

    abstract:Background:Deleted in breast cancer 1 (DBC1) is believed to be involved in human cancers. However, it is still uncertain whether DBC1 expression can be regarded as a prognostic factor in patients with various cancers. This meta-analysis aimed to evaluate the relationship between high levels of DBC1 and prognosis in tum...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S189618

    authors: Liu G,Wu Q,Wang Y,Xiong Q,Fu F

    更新日期:2019-02-22 00:00:00

  • Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.

    abstract::Targeted therapies against EGFR, vascular endothelial growth factor, and vascular endothelial growth factor receptor have expanded treatment options for patients with metastatic colorectal cancer (mCRC). Unfortunately, biomarkers to identify patients that are most likely to derive benefit from targeted therapies in th...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S68558

    authors: Patel SB,Gill D,Garrido-Laguna I

    更新日期:2015-12-30 00:00:00

  • Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.

    abstract:PURPOSE:This study aimed to explore the molecular mechanisms associated with bisphosphonate (BP)-related osteonecrosis of the jaw (ONJ) in patients with multiple myeloma (MM). METHODS:The gene expression profile GSE7116 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) fro...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S88463

    authors: Sun J,Wen X,Jin F,Li Y,Hu J,Sun Y

    更新日期:2015-09-22 00:00:00

  • Scalp metastases as first presentation of pulmonary adenocarcinomas: a case report.

    abstract::Cutaneous metastasis from primary visceral malignancy is a relatively uncommon clinical entity, with a reported incidence ranging from 0.22% to 12% of all malignancies. Here we report a 64-year-old asymptomatic female patient with Peutz-Jeghers syndrome presenting with multiple scalp metastases as the initial manifest...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S174577

    authors: Yu Q,Subedi S,Tong Y,Wei Q,Xu H,Wang Y,Gong Y,Shi Y

    更新日期:2018-09-21 00:00:00

  • Restoration of miR-20a expression suppresses cell proliferation, migration, and invasion in HepG2 cells.

    abstract:OBJECTIVE:To study microRNA (miR)-20a expression in hepatocellular carcinoma (HCC) and its effects on the proliferation, migration, and invasion of HepG2. METHODS:The real-time polymerase chain reaction was used to detect the expression of miR-20a in HCC tissue and normal tissue, as well as in HCC cell lines and norma...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S96861

    authors: Chen GS,Zhou N,Li JQ,Li T,Zhang ZQ,Si ZZ

    更新日期:2016-05-27 00:00:00

  • Lupeol inhibits growth and migration in two human colorectal cancer cell lines by suppression of Wnt-β-catenin pathway.

    abstract:Background:Lupeol, a triterpene isolated from various herbal plants, possesses an anti-inflammatory function and has been proposed as a candidate for anticancer agents. The purpose of this research was to investigate the effect of lupeol on the viability, apoptosis, cell-cycle distribution, and migration of colorectal ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,收录出版

    doi:10.2147/OTT.S183925

    authors: Wang Y,Hong D,Qian Y,Tu X,Wang K,Yang X,Shao S,Kong X,Lou Z,Jin L

    更新日期:2018-11-09 00:00:00

  • STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review.

    abstract::Non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) rearrangement benefit from treatment with ALK inhibitors. Therefore, the identification of druggable ALK fusions is necessary for NSCLC treatment. More than 90 fusion partners of ALK have been reported in NSCLC patients, but the striatin...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S282933

    authors: Su C,Jiang Y,Jiang W,Wang H,Liu S,Shao Y,Zhao W,Ning R,Yu Q

    更新日期:2020-12-04 00:00:00

  • Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma.

    abstract:BACKGROUND:This meta-analysis aimed to assess available evidence on possible associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma (HCC). METHODS:PubMed, EMBASE, Google Scholar, and the Chinese National Knowledge Infrastructure datab...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S104904

    authors: Zhang Y,Zhu SL,Chen J,Li LQ

    更新日期:2016-05-30 00:00:00

  • Long Noncoding RNA LINC00460 Promotes Hepatocellular Carcinoma Progression via Regulation of miR-342-3p/AGR2 Axis.

    abstract:Background:Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide. LINC00460, a novel long non-coding RNA (lncRNA), was recently confirmed as an oncogene in various cancers. However, the biological function and underlying mechanism of LINC00460 in HCC is largely obscure. Methods:Fifty pa...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S239258

    authors: Yang J,Li K,Chen J,Hu X,Wang H,Zhu X

    更新日期:2020-03-06 00:00:00

  • Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors.

    abstract::Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor, and surgical resection is the first choice for the treatment of the disease, but since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib (IM), the prognosis of the disease has undergone revolutionary changes. According to the cu...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S279998

    authors: Xu H,Liu Q

    更新日期:2021-01-05 00:00:00

  • Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.

    abstract::Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. Clinical benefits of trastuzumab have been established in the treatment of both early and metastatic HE...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S27733

    authors: Hamizi S,Freyer G,Bakrin N,Henin E,Mohtaram A,Le Saux O,Falandry C

    更新日期:2013-01-01 00:00:00

  • Dendrobium candidum inhibits MCF-7 cells proliferation by inducing cell cycle arrest at G2/M phase and regulating key biomarkers.

    abstract:BACKGROUND:Breast cancer is one of the most frequently occurring cancers in women. In recent years, Dendrobium candidum has played a part in antihyperthyroidism and anticancer drugs. This study aims to examine the antitumor effect of D. candidum on breast cancer. METHODS:Human breast cancer cell line MCF-7 and normal ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S93305

    authors: Sun J,Guo Y,Fu X,Wang Y,Liu Y,Huo B,Sheng J,Hu X

    更新日期:2015-12-21 00:00:00

  • Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.

    abstract::Discovered in 2007, anaplastic lymphoma kinase (ALK) gene rearrangements positive (ALK+) lung cancers compose a small subset of non-small cell lung cancer (NSCLC), with rapidly expanded treatments. There are currently several ALK inhibitors, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib which ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S174548

    authors: Karachaliou N,Fernandez Bruno M,Bracht JWP,Rosell R

    更新日期:2019-06-13 00:00:00

  • Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.

    abstract:Background:Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx regimen, reporting in...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S194745

    authors: Cortellini A,Cannita K,Parisi A,Lanfiuti Baldi P,Venditti O,D'Orazio C,Dal Mas A,Calvisi G,Giordano AV,Vicentini V,Vicentini R,Felicioni L,Marchetti A,Buttitta F,Russo A,Ficorella C

    更新日期:2019-03-25 00:00:00

  • Identification of key genes and pathways in seminoma by bioinformatics analysis.

    abstract::Background: Seminoma accounts for the most part of cases of testicular germ cell tumor, which is the most common malignancy among males between ages 15 and 44 years. Understanding the molecular mechanism of tumorigenesis is important for better clinical diagnosis and treatment. Purpose: We performed bioinformatics ana...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S199115

    authors: Chen YH,Lin TT,Wu YP,Li XD,Chen SH,Xue XY,Wei Y,Zheng QS,Huang JB,Xu N

    更新日期:2019-05-14 00:00:00

  • SNHG3 Knockdown Suppresses Proliferation, Migration and Invasion, and Promotes Apoptosis in Non-Small Cell Lung Cancer Through Regulating miR-216a/ZEB1 Axis.

    abstract:Background:Tumour growth and development are dependent on many factors including long noncoding RNAs (lncRNAs). However, limited information is available on the involvement of lncRNAs in non-small cell lung cancer (NSCLC) and the molecular mechanisms have not been defined. Here, we examined the expression of small nucl...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S263637

    authors: Zhao S,Gao X,Zhong C,Li Y,Wang M,Zang S

    更新日期:2020-11-04 00:00:00

  • Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma.

    abstract:Objective:This study aimed to evaluate the safety and efficacy of intensity-modulated radiotherapy (IMRT) plus nimotuzumab with or without concurrent chemotherapy (CCT) for patients with locally advanced nasopharyngeal carcinoma (LA-NPC). Patients and methods:A total of 50 newly diagnosed patients with LA-NPC treated ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S151554

    authors: Huang J,Zou Q,Qian D,Zhou L,Yang B,Chu J,Pang Q,Wang K,Zhang F

    更新日期:2017-12-08 00:00:00

  • Inhibition of Mus81 by siRNA enhances sensitivity to 5-FU in breast carcinoma cell lines.

    abstract:PURPOSE:One of the most challenging aspects of breast carcinoma chemotherapy is the rapid acquirement of drug resistance. Improving the sensitivity to chemotherapeutic drugs is very important for successful treatment. Mus81 plays an important role in maintaining the stability of the genome and DNA repair. However, rece...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S64339

    authors: Qian Y,Liu Y,Yan Q,Lv J,Ni X,Wu Y,Dong X

    更新日期:2014-10-21 00:00:00

  • Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.

    abstract::Basal cell carcinoma (BCC) is a common malignant tumor throughout the world. One of the known risk factors of BCC is intense exposure to ultraviolet radiation. More than 50% of BCCs of the eyelid initially occur on the lower lid. The gold standard of diagnosis of BCC is histopathology. Treatment options for BCC consis...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S130371

    authors: Shi Y,Jia R,Fan X

    更新日期:2017-05-08 00:00:00